In the latest quarter, 4 analysts provided ratings for Kymera Therapeutics (NASDAQ:KYMR), showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Insights from analysts’ 12-month price targets are revealed, presenting an average target of $39.5, a high estimate of $55.00, and a low estimate of $26.00. Surpassing the previous average price target of $38.00, the current average has increased by 3.95%. Exploring Analyst Ratings: An In-Dep…